Viridian Therapeutics (VRDN) risk factors, FY2024 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future
2. 02If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts
3. 03We have never generated any revenue from product sales and may never be profitable
4. 04Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights
5. 05Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses

Risks Related to the Discovery and Development of Our Product Candidates

1. 06Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities
2. 07Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements
3. 08Regulatory approval processes are lengthy, time-consuming and inherently unpredictable. Failure to obtain regulatory approval for our product candidates would have a material adverse effect upon our business and business prospects
4. 09Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of approved labeling, or result in significant negative consequences following marketing approval, if any
5. 10in development, may negatively affect clinical trials for our product candidates, delay regulatory approval or result in restrictive drug labeling, if approved
6. 11Additional time may be required to obtain marketing authorizations for certain of our product candidates because they are, or are anticipated to be, combination products
7. 12Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier nonclinical studies and clinical trials may not be predictive of future clinical trial results
8. 13Preliminary data from our clinical trials that we announce or publish are subject to audit and verification procedures that could result in material changes in the final data
9. 14We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success
10. 15commercialization rights to such product candidate. We may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement
11. 16As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition, or results of operations

Risks Related to Commercialization of Our Product Candidates

1. 17If we are unable to establish commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell our product candidates, we may be unable to generate any revenue
2. 18We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans
3. 19We face substantial competition, and our competitors may discover, develop, or commercialize products faster or more successfully than us
4. 20If our competitors obtain marketing approval from the FDA, EMA, or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market
5. 21Our products may not be widely adopted by patients, payors or healthcare providers, which would adversely impact our potential profitability and future business prospects
6. 22Failure to obtain or maintain adequate pricing, reimbursement or insurance coverage for our products, if any, could limit our ability to market those products and decrease our ability to generate revenue
7. 23If we are unable to successfully develop internal commercialization capabilities, sales of our future products may be negatively impacted

Risks Related to Our Reliance on Third Parties

1. 24Our manufacturing processes are complex, and we may encounter difficulties in production, which would delay or prevent our ability to provide a sufficient clinical or commercial supply of our product candidates or products
2. 25In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not appropriately conducted and test data are not reliable, patients could be put at risk of serious harm, and this could result in product liability suits
3. 26We may be unable to realize the potential benefits of any collaboration

Risks Related to Our Intellectual Property

1. 27We may not have sufficient patent term protections for our product candidates to effectively protect our business
2. 28If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets
3. 29Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts
4. 30manufacture or market our product candidates as planned, absent such a license, which may not be available to us on commercially reasonable terms, or at all
5. 31The patent protection and patent prosecution for some of our product candidates are dependent on third parties
6. 32Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 33If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business, which would harm our business
8. 34We may be involved in lawsuits or post-grant review proceedings to defend, protect, or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful
9. 35misleading statement, during prosecution. The outcome following legal assertions of invalidity, unenforceability, and patentability is unpredictable
10. 36We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
11. 37We may be subject to claims challenging the inventorship of our patents and other intellectual property
12. 38We may not be able to protect our intellectual property rights throughout the world
13. 39products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally

Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters

1. 40We expect the product candidates we develop will be regulated as biologics, and they may be subject to competition from biosimilar and interchangeable biological products
2. 41We are no longer pursuing orphan drug designation for veligrotug for thyroid eye disease in the U.S., but we may seek orphan drug designation for veligrotug in other indications and/or territories and for our other product candidates in various indications and/or territories
3. 42We may seek Fast Track, Breakthrough Therapy, and/or Priority Review designations for one or more of our product candidates, but we might not receive such designation(s), and even if we do, such designation(s) may not actually lead to a faster development or regulatory review or approval process
4. 43We may be subject, directly or indirectly, to foreign, federal, and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, sanctions, or other liability
5. 44If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition, or results of operations
6. 45Our use of artificial intelligence (AI) or other emerging technologies could adversely impact our business and financial results

Risks Related to Our Business Operations

1. 46Our future success depends in part on our ability to attract, retain, and motivate qualified personnel. If we lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop our product candidates will be impaired and our business may be harmed
2. 47We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations
3. 48The Hercules Loan and Security Agreement contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation
4. 49Failure in our information technology and storage systems, or those of third parties upon whom we rely, could significantly disrupt the operation of our business and adversely impact our financial condition
5. 50Furthermore, parties in our supply chain may be operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business
6. 51Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited
7. 52Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations
8. 53Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts

Risks Related to Ownership of our Common Stock

1. 54Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
2. 55Our Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees
3. 56We do not anticipate that we will pay any cash dividends in the foreseeable future
4. 57Future sales of shares by existing stockholders could cause our stock price to decline
5. 58Future sales and issuances of equity and debt could result in additional dilution to our stockholders
6. 59Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
7. 60The market price of our common stock has historically been volatile, and the market price of our common stock may drop in the future
8. 61We may be subject to risks related to litigation and other legal proceedings that may materially adversely affect our business, operating results or financial condition
9. 62We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies
10. 63If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline
11. 64If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may be negatively affected
12. 65Our inability to maintain effective internal control over financial reporting in the future could result in investors losing confidence in the accuracy and completeness of our financial reports and negatively affect the market price of our common stock